Tarsons Products Limited has announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The company published these results in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance Overview

The company demonstrated solid financial performance during the third quarter of FY26. The results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 06, 2026.

Quarterly Financial Results

Nine Months Performance

For the nine months ended December 31, 2025, Tarsons Products reported total income from operations of ₹2,573.87 crores compared to ₹2,387.67 crores in the corresponding period of the previous year. Net profit after tax for the nine-month period stood at ₹171.94 crores versus ₹270.02 crores in the previous year.

Consolidated Results

On a consolidated basis, the company reported total income from operations of ₹1,163.15 crores for Q3 FY26, compared to ₹965.26 crores in the same quarter of the previous year. Consolidated net profit after tax was ₹50.36 crores for the quarter, compared to ₹52.59 crores in Q3 FY25.

Key Financial Metrics

Regulatory Compliance

The financial results were published in newspapers on February 08, 2026, as required under Regulation 47 of the SEBI Listing Regulations. The publications appeared in:

• Financial Express (English - National Publication)
• Aajkal (Bengali - Kolkata Publication)

The complete financial results along with Limited Review Reports are available on the stock exchange websites at www.bseindia.com and www.nseindia.com , as well as on the company's website at www.tarsons.com .

Board Approval

The results were formally approved at the Board of Directors meeting held on Friday, February 06, 2026. The company has provided QR codes for easy access to the complete financial statements and related documents through digital platforms.

Tarsons Products announced its Q3FY26 quarterly results for the quarter ended December 31, 2025, alongside several key corporate decisions during a board meeting held on February 06, 2026. The company delivered mixed consolidated financial performance with strong revenue growth offset by margin pressures from new facility investments. Following the results announcement, the company has made the investor conference call recording available to stakeholders.

Q3FY26 Financial Performance Overview

The company's Q3FY26 results present contrasting trends across key financial metrics. While revenue and EBITDA demonstrated robust year-on-year growth, both EBITDA margins and net profitability faced headwinds during the reporting period due to accelerated depreciation and finance costs from new facilities.

Revenue Growth and Geographic Performance

Tarsons Products reported consolidated revenue of ₹1,078.93 million for Q3FY26, representing growth of 12.8% year-on-year from ₹956.77 million in Q3FY25. The company's geographic revenue mix showed India contributing ₹839.77 million and Germany contributing ₹239.16 million during the quarter.

For the nine-month period ended December 31, 2025, consolidated revenue reached ₹3,015.86 million, marking an 8% increase from ₹2,797.23 million in 9MFY25.

Board Meeting Outcomes and Corporate Changes

The board meeting, which commenced at 11:30 A.M. (IST) and concluded at 12:10 P.M. (IST), approved several significant corporate decisions alongside the quarterly results.

Leadership Changes and Board Reconstitution

The company appointed Mr. Vinesh Mohan Kriplani (DIN: 08212644) as Additional Director in the Non-Executive Independent Director category for a term of five consecutive years, subject to shareholder approval. Mr. Kriplani brings over 29 years of experience in Indian corporate and international taxation, specializing in mergers and acquisitions and corporate restructuring.

Simultaneously, Mr. Girish Paman Vanvari (DIN: 07376482) resigned from his position as Independent Director effective February 06, 2026, citing personal commitments. His resignation also resulted in his cessation as chairperson of the Audit Committee and Risk Management Committee.

Strategic Investment in Singapore Operations

The board approved an equity infusion of EUR 3 Million in its wholly-owned subsidiary, Tarsons Life Science Pte. Ltd., incorporated in Singapore. This additional capital infusion is intended to fund the subsidiary's operational and financial expenses, with completion scheduled in quarterly tranches by March 31, 2027.

Investor Conference Call Recording Available

Following the results announcement, the company has uploaded the audio recording of the investor conference call held on February 06, 2026, to discuss the Q3FY26 unaudited financial results. The recording is now accessible on the company's website, providing stakeholders with detailed insights into the financial performance and management commentary.

The company has informed both BSE and NSE about the availability of the conference call recording under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The transcript of the conference call will be shared with the stock exchanges in due course and uploaded on the company's website.

Exceptional Items Impact

The company reported exceptional items of ₹13.48 million in Q3FY26, primarily due to the statutory impact of new labour codes implemented by the Government of India. Under the new unified framework comprising four Labour Codes, the company recognized past service costs arising from changes in the definition of wages and employee benefit plans.